Brief: Integragen Presents Positive Data From Liquid Biopsy Studies Of miRNAs

IntegraGen SA

12/04/2018 07:06

April 12 (Reuters) - INTEGRAGEN SA  ALINT.PA :
    * INTEGRAGEN PRESENTS POSITIVE DATA FROM LIQUID BIOPSY
STUDIES OF
COMPANY’S PROPRIETARY MIRNAS DURING 2018 EUROPEAN LUNG CANCER
CONFERENCE
    * CO'S PROPRIETARY MIRNA BIOMARKERS PREDICT EGFR TYROSINE
KINASE
INHIBITOR (EGFR-TKI) TREATMENT RESPONSE
    * MIRNA BIOMARKERS IDENTIFY DRUG RESISTANCE EMERGENCE IN
LUNG
ADVANCED SQUAMOUS CELL CARCINOMA PATIENTS

Source text for Eikon:  ID:nBwc0KPyKa 
Further company coverage:  ALINT.PA 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))